Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHA:600613)
China · Delayed Price · Currency is CNY 6.27
+0.07 (1.13%)
Feb 3, 2026, 3:00 PM CST
SHA:600613 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,883 | 2,048 | 2,340 | 2,388 | 2,300 | 1,819 |
Other Revenue | 0.51 | 0.51 | 0.68 | 0.22 | 2.92 | 0.38 |
| 1,883 | 2,049 | 2,341 | 2,389 | 2,303 | 1,819 | |
Revenue Growth (YoY) | -14.14% | -12.48% | -2.00% | 3.72% | 26.61% | -5.63% |
Cost of Revenue | 1,038 | 1,097 | 1,189 | 1,125 | 918.13 | 747.6 |
Gross Profit | 845.43 | 951.71 | 1,152 | 1,263 | 1,385 | 1,071 |
Selling, General & Admin | 690.43 | 784.63 | 1,002 | 1,097 | 1,232 | 1,008 |
Research & Development | 22.75 | 32.89 | 32.3 | 45.99 | 50.95 | 42.79 |
Other Operating Expenses | 28.97 | 24.58 | 26.51 | 29.62 | 27.22 | 21.55 |
Operating Expenses | 753.05 | 858.28 | 1,025 | 1,178 | 1,294 | 1,183 |
Operating Income | 92.38 | 93.43 | 126.37 | 85.79 | 90.69 | -111.57 |
Interest Expense | -11 | -12.8 | -14.76 | -17.37 | -8.34 | -4.94 |
Interest & Investment Income | 9.48 | 10.85 | 5.97 | 8.17 | 30.51 | 1.96 |
Currency Exchange Gain (Loss) | -0.12 | -0.12 | 0 | 0 | -0 | -0 |
Other Non Operating Income (Expenses) | 0.1 | -1.19 | 11.79 | -13.91 | 6.17 | -67.71 |
EBT Excluding Unusual Items | 90.83 | 90.17 | 129.37 | 62.69 | 119.03 | -182.26 |
Impairment of Goodwill | - | - | -55.21 | - | - | -162.08 |
Gain (Loss) on Sale of Investments | 1.3 | -0.02 | 0.9 | - | - | - |
Gain (Loss) on Sale of Assets | -0.5 | -0.37 | 0.17 | -5.23 | -0 | -1 |
Asset Writedown | -13.11 | -1.47 | -0.47 | -2.72 | -26.72 | -0.13 |
Other Unusual Items | 2.01 | -0.73 | 8.66 | 8.49 | 7.29 | 5.19 |
Pretax Income | 80.52 | 87.58 | 83.41 | 63.23 | 99.6 | -340.28 |
Income Tax Expense | 22.17 | 21.5 | 25.15 | 14.93 | 31.64 | 13.19 |
Earnings From Continuing Operations | 58.35 | 66.08 | 58.26 | 48.29 | 67.96 | -353.47 |
Minority Interest in Earnings | 3.98 | 5.31 | -1.26 | 0.25 | 1.66 | 12.27 |
Net Income | 62.34 | 71.39 | 57 | 48.55 | 69.62 | -341.2 |
Net Income to Common | 62.34 | 71.39 | 57 | 48.55 | 69.62 | -341.2 |
Net Income Growth | 23.67% | 25.24% | 17.41% | -30.27% | - | - |
Shares Outstanding (Basic) | 564 | 549 | 518 | 539 | 536 | 533 |
Shares Outstanding (Diluted) | 564 | 549 | 518 | 539 | 536 | 533 |
Shares Change (YoY) | 10.37% | 5.97% | -3.94% | 0.72% | 0.46% | 1.58% |
EPS (Basic) | 0.11 | 0.13 | 0.11 | 0.09 | 0.13 | -0.64 |
EPS (Diluted) | 0.11 | 0.13 | 0.11 | 0.09 | 0.13 | -0.64 |
EPS Growth | 12.05% | 18.18% | 22.22% | -30.77% | - | - |
Free Cash Flow | 139.68 | 171.39 | 191.08 | 292.59 | 98.3 | 2.79 |
Free Cash Flow Per Share | 0.25 | 0.31 | 0.37 | 0.54 | 0.18 | 0.01 |
Dividend Per Share | 0.150 | 0.150 | 0.100 | 0.100 | 0.100 | - |
Dividend Growth | 50.00% | 50.00% | - | - | - | - |
Gross Margin | 44.89% | 46.45% | 49.20% | 52.90% | 60.13% | 58.90% |
Operating Margin | 4.91% | 4.56% | 5.40% | 3.59% | 3.94% | -6.13% |
Profit Margin | 3.31% | 3.48% | 2.44% | 2.03% | 3.02% | -18.76% |
Free Cash Flow Margin | 7.42% | 8.37% | 8.16% | 12.25% | 4.27% | 0.15% |
EBITDA | 167.56 | 171.19 | 207.57 | 170.59 | 147.2 | -58.69 |
EBITDA Margin | 8.90% | 8.36% | 8.87% | 7.14% | 6.39% | -3.23% |
D&A For EBITDA | 75.19 | 77.76 | 81.2 | 84.8 | 56.51 | 52.88 |
EBIT | 92.38 | 93.43 | 126.37 | 85.79 | 90.69 | -111.57 |
EBIT Margin | 4.91% | 4.56% | 5.40% | 3.59% | 3.94% | -6.13% |
Effective Tax Rate | 27.53% | 24.55% | 30.15% | 23.62% | 31.76% | - |
Revenue as Reported | 1,883 | 2,049 | 2,341 | 2,389 | 2,303 | 1,819 |
Advertising Expenses | - | - | - | - | - | 399.83 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.